a bit more from immutep on soft tissue sarcoma research with...

a bit more from immutep on soft tissue sarcoma research with polish investigators.....

Immutep CEO, Marc Voigt, said: “We were delighted to be approached by Dr Paweł Sobczuk and Dr.
Katarzyna Kozak to form this collaboration with the Maria Skłodowska-Curie National Research Institute of
Oncology to explore the potential of efti in combination with pembrolizumab and radiotherapy in soft tissue
sarcoma. We thank the Polish government for granting €1.5M in non-dilutive cash funding for this trial.
Recurrence and lack of deep and durable responses are challenges with the limited standards of care available
for this rare and difficult-to-treat disease. Efti’s novel mechanism of action offers potential to enhance antitumour responses for these patients. This latest expansion of the efti pipeline is further evidence of the
increased interest from a variety of interested parties to investigate the broad potential of efti to improve
patient outcomes in yet another cancer indication and treatment regimen.”
Immutep Limited, Level 33, Australia Square
264 George Street, Sydney NSW 2000
ABN: 90 009 237 889
Immutep CSO and CMO, Dr Frederic Triebel said: “Efti stimulates the immune system through a
differentiated mechanism that targets LAG-3-driven activation of antigen-presenting cells. By working
upstream of T cells, efti has potential to generate a broad and robust anti-tumour immune response even in
the immunosuppressed tumour microenvironment of soft tissue sarcomas. Therefore, we are very pleased to
be collaborating with our colleagues at the Maria Skłodowska-Curie National Research Institute of Oncology.”
Maria Skłodowska-Curie National Research Institute of Oncology, Medical Oncology Fellow and CoPrincipal Investigator, Dr. Paweł Sobczuk said: “The need for new approaches in this rare and aggressive
disease is evident by the still dismal responses with current standards of care including surgery, radiotherapy
and chemotherapy. Clinical data in other solid tumours suggest that efti can synergize with radiotherapy and
pembrolizumab for robust responses across PD-L1 status, supporting the potential of this combination to
mount effective immunity against aggressive malignancies like soft tissue sarcoma and replace the need for
chemotherapy.”